RecruitingNot ApplicableNCT06372730

Residual Pulmonary Vascular Obstruction Index Computed with Ventilation/perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients with Pulmonary Embolism (PRONOSPECT)

Residual Pulmonary Vascular Obstruction (RPVO) Index Computed with Ventilation/perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism (VTE) Recurrence in Patients with Pulmonary Embolism (PE)


Sponsor

University Hospital, Brest

Enrollment

665 participants

Start Date

Jun 11, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk. Little is known about this last group. Anticoagulation is efficient to prevent recurrence but is currently not recommended for patient with an intermediate risk of recurrence. Identifying risk factors of recurrent PE remains a major issue to identify sub-groups of patients who would require lifelong anticoagulation. In 30-40% of cases, PE patients develop residual pulmonary vascular obstruction (RPVO), which has been found to be associated with an increased recurrence risk. This last observation was mostly reported in patients with unprovoked PE (patients with high risk of recurrence) and RPVO was measured using conventional planar lung scan. In patients with an intermediate risk of recurrence, the impact of RPVO has been much less studied. In addition, the definition of RPVO was variable according to studies and correlation between RPVO burden and recurrence risk has not been clearly demonstrated. This might be explained by the inherent limitation of RPVO quantification using conventional planar imaging, which is only based on a visual estimation on 2-dimensional images. Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT) is a new method of scintigraphic image acquisition that offers the advantage of 3-dimensional imaging, enabling more accurate and reproducible quantification of RPVO. The main hypothesis of this study is that in patients with PE at intermediate risk of recurrence, RPVO computed with V/Q SPECT/CT imaging may be an important predictor of recurrence.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Patients ≥ 18 years,
  • who experienced an objectively proven PE,
  • who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.

Exclusion Criteria9

  • Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)
  • Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and patients admitted to a health or social establishment for purposes other than research
  • No Social security affiliation
  • Isolated DVT
  • Pregnant women,parturients women
  • Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)
  • Life expectancy < 6 months
  • Any patients for whom there is a strong indication to treat longer than 6 months: PE provoked by a major persistent factor (e.g. cancer) or Recurrent unprovoked PE
  • PE provoked by a major transient risk factor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERVentilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)

All patients will undergo a V/Q SPECT/CT scan at inclusion.


Locations(13)

CHU Amiens

Amiens, France, France

CHU Angers

Angers, France, France

CHU Brest

Brest, France, France

Hôpital Louis MourierAP-HP

Colombes, France, France

CHD Vendée - La Roche sur Yon

La Roche-sur-Yon, France, France

Kremlin-Bicêtre AP-HP

Le Kremlin-Bicêtre, France, France

CH Les Sables d'Olonne

Les Sables-d'Olonne, France, France

Hegp Ap-Hp

Paris, France, France

CH Quimper

Quimper, France, France

CHU St-Etienne

Saint-Etienne, France, France

CHIC Toulon

Toulon, France, France

HIA Toulon

Toulon, France, France

CHU Toulouse

Toulouse, France, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06372730


Related Trials